Business Wire

CA-PSMF

3.6.2023 07:12:31 CEST | Business Wire | Press release

Share
The Patient Safety Movement Foundation Concludes Its 10th Annual World Patient Safety, Science & Technology Summit

President Bill Clinton, 42nd President of the United States, headlined day two of the 10th Annual World Patient Safety, Science & Technology Summit, presented by the Patient Safety Movement Foundation (PSMF).

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230602005417/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Joe Kiani, founder of the Patient Safety Movement Foundation, discusses efforts to improve patient safety worldwide with former President Bill Clinton at the 10th Annual World Patient Safety, Science & Technology Summit in Newport Beach, California. (Photo: Business Wire)

As a long-time advocate of patient safety, President Clinton spoke of the need to develop what he termed a “culture of conversion,” where more people within healthcare feel empowered to implement proven practices for eliminating preventable harm within hospitals.

“We know enough right now to cut the current problem by half or more,” he said. “One of the biggest problems you have in every big, complicated society is that there’s an incredibly built-in resistance to being the second, third, fourth, or 100th person to do the same thing, even though it’s been proven to work. Which is exactly the reverse of what we should be doing.”

Reflecting on his time in office during the 1990s, President Clinton said that we could learn much from the example of former South African President Nelson Mandela when it comes to uniting people behind a common cause for good.

“Everyone wants to believe they have some piece to add to life’s great puzzle,” he said. “You need converts to do anything big, and we’ve got to get more zealous converts. Nelson Mandela was a genius at this. He was the best I ever saw. He never tried to make people feel bad for what they hadn’t done. He tried to make people feel good about what they could do.”

Having long been a campaigner on the dangers of the opioid epidemic and a supporter of the PSMF since its inception, President Clinton suggested that it is important to focus on collaborating for future good rather than blaming and shaming when it comes to medical errors.

“No one wants to see innocent people die, and very few are hard-hearted enough not to care,” he said. “You don’t have to save everybody; you just have to save everybody that you can.”

Dr. Michael Ramsay, chief executive officer of the PSMF, told the audience that there is much cause for optimism when it comes to meeting the target of zero preventable deaths by 2030. “I think there’s a future now to patient safety,” he said. “I think things are going to start happening remarkably fast. Technology is changing, we’re gathering more data, and we’ve got more and more people involved in this movement.”

Jeremy Hunt, chancellor of the exchequer of the United Kingdom, delivered a video message to the Summit in which he applauded the difference made by the PSMF over the last decade. “We now have the World Health Organization doing an annual World Patient Safety Day, a 10-year plan to reduce preventable deaths, and we had a ministerial summit this year in Montreux in Switzerland with more than 100 countries represented. We’re making great progress, but there’s a lot of work to do. Even one preventable death is too many. We should be aiming for zero.”

Following on from President Clinton’s remarks about creating the right culture for change within healthcare, Anthony Staines, patient safety program director, Fédération des hôpitaux vaudois, Switzerland, described the need to address the failings of implementation science, a topic also addressed in a talk from Francisco Valero-Cuevas, a professor at the University of Southern California.

“There are many prevention and mitigation solutions, but they are only partly and unsystematically applied,” said Staines. “Science has brought us an expanding body of knowledge. The trouble is that it does not reach the patients.”

There were additional talks from Peter Ziese, chief medical officer at Philips, and Michelle Schreiber of the Centers for Medicare & Medicaid Services. Schreiber told the audience that while healthcare throughout the United States has made significant improvements in patient safety, the pandemic illustrated how our systems are still not durable and resilient enough for times of stress, and gaps in care and infrastructure continue to persist.

Mike Durkin and Sanaz Massoumi, chairman and chief operating officer of the PSMF respectively, gave addresses, and panel discussion topics included the media’s role in covering patient safety, opioid safety, and steps that can be taken in the journey to zero harm. Marcelo Ebrard Casaubón, secretary of foreign affairs of Mexico, received the Joe Kiani Humanitarian Award for his work in patient safety.

Finally, Kiani, founder of the PSMF, reflected on a decade of achievement and the path forward. “We started as a grassroots organization, and the grassroots movement has done so much,” he said. “I think our next step is to demand our elected officials to hardwire patient safety into our system and align the incentives so that every hospital puts evidence-based practices in place.”

ABOUT THE PATIENT SAFETY MOVEMENT FOUNDATION

In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals. His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges. The AEBP are available without charge to hospitals online. Hospitals are encouraged to make a formal commitment to ZERO preventable deaths, and healthcare technology companies are asked to sign the Open Data Pledge to share their data so that predictive algorithms that can identify errors before they become fatal can be developed. The Foundation's annual World Patient Safety, Science & Technology Summit brings together all stakeholders, including patients, healthcare providers, medical technology companies, government employers, and private payers. The PSMF was established through the support of the Masimo Foundation for Ethics, Innovation, and Competition in Healthcare. For more information, please visit psmf.org.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230602005417/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release

Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around

Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release

Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5

HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release

HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye